SCHEDULE: Vanguard Boosts Stake in Avidity Biosciences to 9.57%

The Vanguard Group has increased its beneficial ownership in Avidity Biosciences Inc. to 9.57% of common stock as of September 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 13,219,759 shares of Avidity Biosciences Inc. common stock.
• This represents 9.57% of the class of securities.
• Vanguard holds sole dispositive power over 12,196,279 shares and shared dispositive power over 1,023,480 shares.
• Vanguard holds shared voting power over 878,441 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by a large institutional investor. While an increased stake by Vanguard can be seen as a positive signal, it is a factual report without explicit forward-looking statements or performance metrics. The sentiment is mildly positive due to the increased institutional holding.

Positives

• The Vanguard Group, a major institutional investor, increasing its stake could be interpreted as a vote of confidence in Avidity Biosciences Inc.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Avidity Biosciences, a biotechnology company. Large passive investment managers like Vanguard often accumulate significant stakes in companies across various sectors, reflecting their broad market exposure strategies rather than specific industry-driven insights for individual companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a major fund like Vanguard may provide a degree of stability and confidence in the stock.

Key Dates

Keywords

Avidity Biosciences Inc, The Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake